Keywords: aptanomics, validate, targets, boeh, ingelheim, germany, boehringer
Aptanomics to validate targets for Boeh Ingelheim
Article | 08 August 2005
Germany's Boehringer Ingelheim and Aptanomics SA, a French specialist in the application of innovative peptide aptamer technologies for drug discovery, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
